<DOC>
	<DOCNO>NCT02166281</DOCNO>
	<brief_summary>Insomnia common Breast cancer patient adjuvant therapy aromatase inhibitor . However difficult establish whether due knowledge disease treatment administred . The investigator design cohort study questionnaires assessment sleep quality ( Pittsburgh Sleep Quality Index Insomnia Severity Index ) , anxiety ( State Trait Anxiety Inventory ) , depression ( Beck Depression Inventory ) , quality life general ( Functional Assessment Cancer Therapy ) evaluation RLS ( Restless Legs Syndrome Rating Scale ) prospectively administer patient early breast cancer baseline adjuvant treatment aromatase inhibitor . As secondary aim investigator also evaluate dietary life ' factor , bear turn BMI .</brief_summary>
	<brief_title>Impact Adjuvant Treatment With Aromatase Inhibitor Sleep Disturbances Postmenopausal Women With Endocrine Responsive Early Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>Women histological diagnosis invasive operate breast cancer ( pT , pN ) Women 60 year Women less 60 year amenorrhea least 12 month FSH estradiol value range menopause Signature write informed consent . Locally advanced metastatic disease ( M1 ) A history breast cancer cancer diagnose last 10 year , exception basal cell carcinoma squamous cell carcinoma skin carcinoma situ cervix History severe osteoporosis diagnosis breast cancer Bisphosphonate therapy diagnosis breast cancer Other serious medical condition could limit ability patient participate study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Insomnia</keyword>
	<keyword>Anxiety</keyword>
	<keyword>Depression</keyword>
	<keyword>Restless leg syndrome</keyword>
	<keyword>Aromatase inhibitor</keyword>
	<keyword>Body composition</keyword>
</DOC>